Skip to main content
. 2025 May 15;16(5):104787. doi: 10.4239/wjd.v16.i5.104787

Table 2.

Various types of maturity-onset diabetes of the young and neonatal diabetes mellitus with the genes involved in the pathogenesis and the clinical features


Subtype
Gene
Frequency
Gene-disease
Clinical feature
Inheritance
MODY MODY 1 HNF4A 14% Classical MODY Fetal macrosomia and/or neonatal hypoglycemia, respond to low-dose SU initially, progressive β-cell failure, require insulin later, risks of complications AD
MODY 2 GCK 22% Mild fasting hyperglycemia does not require treatment except during gestation determined by the GCK mutation status of the foetus AD, rarely AR
MODY 3 HNF1A 33% Disproportionate glucosuria (low renal threshold), response to low-dose SU initially, progressive β-cell failure, require insulin later, risks of complications AD, rarely AR
MODY 4 IPF1/PDX1 < 1% A heterozygous mutation causing MODY or T2DM or homozygous mutation causing PNDM (see below) AD
MODY 5 HNF1B 6% Syndromic MODY Renal cysts and diabetes, pancreas hypoplasia, exocrine insufficiency, β-cell defect, low magnesium, gout, altered LFT, and autism; Require insulin; Risks of complications; 40% are de novo AD
MODY 6 NEUROD1 1% Classical MODY A heterozygous mutation causing MODY or homozygous mutation causing NDM (not mentioned below) AD
MODY 7 KLF11 < 1% Evidence refuted Potentially causing T2DM in the presence of obesity rather than causing MODY AD
MODY 8 CEL < 1% Syndromic MODY Diabetes and pancreatic exocrine dysfunction; Pancreatic cysts may be present AD
MODY 9 PAX4 < 1% Evidence refuted Potentially causing T2DM in the presence of obesity rather than causing MODY AD
MODY 10 INS 2% Classical MODY Mild defects can present as MODY whereas severe defects can present as TNDM or PNDM (as below), insulin treatment preserves β-cell mass and insulin secretion AD
MODY 11 BLK < 1% Evidence refuted Potentially causing T2DM in the presence of obesity rather than causing MODY AD
MODY 12 ABCC8 4% Classical MODY Manifest as relapse following TNDM or as isolated MODY with no history of TNDM, respond to low-dose SU AD
MODY 13 KCNJ11 2% Manifest as relapse following TNDM or as isolated MODY with no history of TNDM, respond to low-dose SU AD
MODY 14 APPL1 < 1% Evidence weak Delayed onset MODY with low penetrance and less severity; Potentially causing T2DM in the presence of obesity rather than causing MODY AD
RFX6-MODY RFX6 < 1% Classical MODY Significantly low penetrance; Likely to respond to DPP4 inhibitors or GLP-1 receptor agonists (low GIP levels are present in these patients) AD
NDM TNDM 45% NDM ZAC and HYMAI 70% TNDM TNDM1 6q24 abnormal uniparental disomy 40%, paternal duplication 40%, maternal hypomethylation 20%, macroglossia, umbilical hernia, cardiac/renal defect, hypothyroidism Sporadic or AD
ABCC8 15% TNDM TNDM2 TNDM (early infancy), remission (early childhood), and/or relapse of diabetes (in adulthood), mild developmental features may be seen, marked response to low-dose SU Sporadic or AD
KCNJ11 10% TNDM TNDM (early infancy), remission (early childhood), and/or relapse of diabetes (in adulthood), mild developmental features may be seen, marked response to low-dose SU Sporadic or AD
INS 5% TNDM IUGR; Doesn’t respond to SU but responds to insulin therapy AD, rarely AR
HNF1B Renal cyst and pancreatic hypoplasia AD
SLC2A2 TNDM, PNDM (rare), or Fanconi-Bickel syndrome (Fanconi syndrome, short stature, rickets, growth retardation, hepatomegaly, and glucose/galactose intolerance) AR
PNDM 45% NDM KCNJ11 50% PNDM DEND (developmental delay, epilepsy, NDM) or iDEND syndrome (mild developmental delay, no epilepsy), severe hyperglycemia, DKA frequent, response to high-dose SU Sporadic or AD
INS 30% PNDM IUGR; Doesn’t respond to SU but responds to insulin therapy AD
ABCC8 15% PNDM DEND (developmental delay, epilepsy, NDM) or iDEND syndrome (mild developmental delay, no epilepsy), severe hyperglycemia, DKA frequent, response to high-dose SU Sporadic, AD or AR
GCK 3% PNDM IUGR; Homozygous mutations causing PNDM requiring lifelong insulin therapy AR
IPF1/PDX1 2% PNDM Pancreatic hypoplasia causing PNDM (homozygous mutation) AR
HNF1B Renal cyst and pancreatic hypoplasia AD
Syndromic NDM; 10% NDM EIF2AK3 Rare PNDM with spondyloepiphyseal dysplasia, and renal anomalies (Wolcott-Rallison syndrome) AR
FOXP3 IPEX syndrome XR
GATA4/6 Permanent neonatal diabetes with pancreatic agenesis and congenital heart defects AD
RFX6 Neonatal diabetes, pancreatic hypoplasia, gallbladder agenesis, intestinal atresia (Mitchell-Riley syndrome) AR
GLIS3 Congenital hypothyroidism, glaucoma, hepatic fibrosis, polycystic kidneys, developmental delay AR
PTF1A Pancreatic and cerebellar hypoplasia AR

MODY: Maturity-onset diabetes of the young; NDM: Neonatal diabetes mellitus; TNDM: Transient neonatal diabetes mellitus; PNDM: Permanent neonatal diabetes mellitus; AD: Autosomal dominant; AR: Autosomal recessive; XR: X-linked recessive; SU: Sulfonylurea; LFT: Liver function test; T2DM: Type 2 diabetes mellitus; DPP4: Dipeptidyl peptidase-4; GLP: Glucagon-like peptide; IUGR: Intrauterine growth restriction; DEND: Developmental delay, epilepsy, neonatal diabetes mellitus; iDEND: Intermediate developmental delay, epilepsy, and neonatal diabetes syndrome; DKA: Diabetic ketoacidosis; IPEX syndrome: Immuno-dysregulation, polyendocrinopathy, enteropathy, X-linked.